Healthy Communities

COVID-19 Guidance On Therapeutics

 

Monoclonal Antibodies

Early treatment and post-exposure prophylaxis

In November, the U.S. Food and Drug Administration issued an Emergency Use Authorization to allow the use of monoclonal antibodies for the treatment of mild to moderate symptoms of COVID-19 in adults and pediatric patients. Monoclonal antibody treatment can be used in people 12 years of age and older who weigh at least 88 pounds (40 kg) who are at high risk for severe COVID-19, including hospitalization or death for:

Bamlanivimab/etesevimab has been authorized by the FDA for early treatment and prevention of COVID 19 in children <12 years of age including newborns.

Prioritization: UPDATED NIH TREATMENT AND PRIORITIZATION STATEMENTS FOR NON HOSPITALIZED PATIENTS WHEN OMICRON IS PREDOMINANT CIRCULATING VARIANT

Attention Providers

HHS has transitioned from direct ordering of monoclonal antibodies to a state-coordinated distribution system. Hospitals and other administration sites will no longer order from AmeriSource Bergen directly. The federal government will determine the total allocation amount for each state based upon state cases and hospitalizations, and utilization as reported to HHS Protect / TeleTracking. ADH will determine which sites will receive MAbs and allocation amount.

Orders must be placed by COB each Monday. The order should be based upon the 7 day average of what your facility uses, and you should only order what you expect to use in one week. Most shipments
will go directly to your facility from Amerisource Bergen. For all new sites, or special circumstances, MAbs will come directly from ADH and delivery will be coordinated with the site.
 
ATTENTION: Click here to place a monoclonal antibody order for your site.
 
MAB Cycles:

​​There are multiple REGEN-COV packaging variations (co-formulated, non-co-formulated doses).  Please verify package inserts upon delivery and follow proper administration procedures for the version your site received.  Additionally, all REGEN-COV products can be administered via intravenous infusion and/or subcutaneous injections.

**ORAL ANTIVIRAL TREATMENTS ARE DRIVE-THRU OR CURBSIDE ONLY! PLEASE DO NOT ENTER STORES!**

Department of Health and Human Services COVID-19 Therapeutics Locator

Oral antivirals

Ritonavir boosted nirmatrelavir (Paxlovid) and molnupiravir were approved under EUA by the FDA for treatment of early COVID 19 infection. These treatments should be given within the first 5 days of symptom onset.  Initial distribution of these oral medications is limited to selected sites and further sites will continue to be added.

Paxlovid and molnupiravir may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs in the therapeutic class to which these drugs belong (i.e., anti-infectives).

**ORAL ANTIVIRAL TREATMENTS ARE DRIVE-THRU OR CURBSIDE ONLY! PLEASE DO NOT ENTER STORES!**

Cycles:

Pre Exposure Prophylaxis

A new monoclonal antibody (tixagevimab/cilgavimab) for the prevention of COVID-19 has been authorized by the FDA under EUA that may be used in immunocompromised patients and patients who have a medical contraindication to receiving a vaccine for COVID-19. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:

Attention providers

ATTENTION: Click here for the survey regarding your facility's interest in receiving pre-exposure prophylaxis (Evusheld).

Evusheld Cycles:

Orders must be placed by COB each Tuesday. The order should be based upon the 7 day average of what your facility uses, and you should only order what you expect to use in one week. Most shipments will go directly to your facility from Amerisource Bergen. For all new sites, or special circumstances, MAbs will come directly from ADH and delivery will be coordinated with the site.
 

Locations in Arkansas Receiving COVID-19 Therapeutics

Resources:

 

 
 

Public Health Accrediation Board
Arkansas Department of Health
© 2017 Arkansas Department of Health. All Rights Reserved. www.healthy.arkansas.gov
4815 W. Markham, Little Rock, AR 72205-3867
1-800-462-0599